Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Medscape Oncologist Lifestyle Report 2015

(Medscape Medical Oncology) Jan 26, 2015 - This Medscape lifestyle survey updates a previous report on oncologists' lifestyle and burnout.

Commentary: Damn, I'm tired...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

FDA Expands Approved Use of Imbruvica For Rare Form of non-Hodgkin Lymphoma

(FDA.gov) Jan 29, 2015 - First drug approved to treat Waldenström’s macroglobulinemia.
read press release »

Putting Precision Medicine For Cancer at Work in America's Largest Hospital

(Forbes) Jan 29, 2015 - In one of the largest initiatives of its kind, the for-profit hospital chain Hospital Corporation of America (HCA) has embarked on a plan to molecularly profile the tumor of cancer patients, marry the genomic information to clinical data from a patient’s electronic health record, and recommend targeted therapies.
read article »

Scoring Progress Against Cancer: New Tool Measures Cancer Progress to Help Inform Research and Policy Decisions

(Lilly) Jan 29, 2015 - On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types.
read corporate press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Medscape Oncologist Lifestyle Report 2015 (Medscape Medical Oncology)

Damn, I'm tired...posted by: Thomas Marsland, MD

Biosimilar Drugs Promise to Cut Patient Costs, But Will Doctors and Insurers Buy Them? (International Business Times)

Biosimilars present an interesting challenge. Generics are really the same compound, produced in similar fashion...posted by: Thomas Marsland, MD

Will Cancer Society's Redo Be Its Undoing? (MedPage Today)

This report hits especially close to home. This will not be the undoing because the ACS has already been undone....posted by: Thomas Marsland, MD

Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer (MarketWatch)

The problem with using PFS as an endpoint here is that these patients tend to live for a long while after treatment...posted by: H. Jack West, MD

Op-Ed: Why Drugs Cost So Much (New York Times)

Well stated. The requirement to cover is definitely a dis-incentive to price reasonably.posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.





FM_ROS_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CBLI +13.48%
ADXS +10.70%
ZIOP +7.58%
XNCR -8.22%
TLOG -4.76%
EXEL -3.43%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

Date: March 8, 2015
Company: Novartis / Sandoz
Product: Zarxio™ (filgrastim, EP2006)

Date: March 2015
Company: Nektar Therapeutics
Product: NKTR-102

See All OBR Radar items»